Neuropace
NPCE
113 hedge funds and large institutions have $348M invested in Neuropace in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 13 closing their positions.
115% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 13
13% more funds holding
Funds holding: 100 → 113 (+13)
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
0.37% less ownership
Funds ownership: 78.96% → 78.59% (-0.37%)
14% less capital invested
Capital invested by funds: $406M → $348M (-$58.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $147K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$16.7M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$6.29M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.44M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.91M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.65M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4.56M |
| 3 |
Walleye Capital
New York
|
-$3.53M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.19M |
| 5 |
AC
Armistice Capital
New York
|
-$1.5M |
NPCE Hedge Fund Activity: Q1 2026 in Review
113 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q1 2026, worth a combined $348M — down 14% from $406M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new NPCE positions and 13 closed out — a net gain of 15 holders — while 39 added to existing stakes and 36 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $16.7M. The largest seller was OrbiMed, cutting an estimated $4.65M.
- 113 institutional investors held Neuropace (NPCE) as of Q1 2026, up from 100 in Q4 2025.
- Funds reported $348M of Neuropace stock for Q1 2026, down 14% quarter-over-quarter.
- 28 funds opened new Neuropace positions in Q1 2026 and 13 closed out, a net change of +15 holders.
- The largest Neuropace buyer in Q1 2026 was First Light Asset Management, an estimated $16.7M added.
- The largest Neuropace seller in Q1 2026 was OrbiMed, an estimated $4.65M sold.
Based on aggregated 13F filings for Q1 2026.